Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathing battle: which technique helps COPD patients breathe easier?

NCT ID NCT07713043

Symptom relief Sponsor: Riphah International University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study compares two airway clearance methods—autogenic drainage (a controlled breathing technique) and a flutter device (a handheld tool that vibrates to loosen mucus)—in people with moderate COPD. Over six weeks, researchers will measure changes in shortness of breath, lung function, and exercise capacity. The goal is to find a simple, non-invasive way to improve daily life for COPD patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autogenic drainage (a breathing technique) and flutter device (a handheld device that uses vibrations to loosen mucus)
What this could lead to
If one technique proves more effective, it could offer a simple, low-cost way to improve breathing and daily function for people with COPD.
What could go wrong
This is a small, short-term study (42 people, 6 weeks), so results may not apply to all COPD patients or show lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age group: Middle age adults (40-60 years), medically stable * Both gender * Diagnosis based on GOLD criteria ((FEV₁/FVC ratio \< 0.70). * Moderate COPD with no acute exacerbations in the past 4-6 weeks. * Participants must be able to perform Autogenic drainage and Flutter device physically and mentally. * Voluntary participation with consent. Exclusion Criteria: * Cardic Diseases (Acute MI, Congestive Heart Failure) * Musculoskeletal Impairements * Using Non-invasive Ventilation * Recent lung diseases (Respiratory failure, pneumothorax) * Hemodynamic instability * Uncoorperative patients * Cognitive Impairement scale * Participants excluded if they did not consent * Comorbidities affecting exercise tolerance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Dyspnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nimra Noor

    Lahore, Punjab Province, 40100, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.